Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).

Sara Elena Rebuzzi,Matteo Bauckneht,Alessio Signori,Viviana Frantellizzi,Elisa Lodi Rizzini,Manlio Mascia,Valentina Lavelli,Maria Lina Stazza,Maria Licari,Maria Isabella Donegani,Marta Ponzano,L. Cavallini,V. Laghi,Luca Cindolo,Renato Costa,Angela Spanu,Giuseppe Rubini,Fabio Monari,Giuseppe De Vincentis,Giuseppe Fornarini

Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).

2021

e17026Background: Ra-223 is a treatment option for mCRPC pts with bone metastases according to the survival benefit observed compared to placebo in the ALSYMPCA trial. In the last years, many studi...

Keywords:

treatment options
inflammatory biomarkers
Oncology
Medicine
survival benefit
Internal medicine
Prostate cancer
peripheral blood
Placebo
castration resistant
Radium-223

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations